Jason Harris

IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion (IKZF1plus) were associated with a dramatically reduced prognosis in pediatric patients with B-cell precursor ALL.

Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.

A blood test that detects early changes in circulating tumor DNA may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to palbociclib (Ibrance).

Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma.

A “robust” 23-gene expression-based model successfully predicted progression-free survival for patients with follicular lymphoma enrolled in the phase III randomized PRIMA trial.

Adjuvant chemotherapy given during and after radiotherapy did not improve 5-year overall survival for patients with high-risk endometrial cancer in the phase III PORTEC-3 trial.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.

Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor.

Pembrolizumab (Keytruda) induced responses in more than one-fifth of patients with recurrent thymic carcinoma who had progressed following 1 or more lines of chemotherapy.

Obese men treated with targeted or immune therapies for metastatic melanoma had a 47% reduced risk of death compared with men who had a normal BMI.

The PI3K-delta inhibitor umbralisib (TGR-1202) induced an objective response rate of 37% in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia.

The survival benefit with adjuvant chemotherapy in ER-negative breast cancer patients with isolated locoregional recurrence was sustained in the final analysis of the phase III CALOR trial.

Low-coverage genome-wide sequencing of cell-free DNA from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer.

Lenvatinib (Lenvima) was noninferior for overall survival while improving progression-free survival compared with sorafenib (Nexavar) for the frontline treatment of patients with unresectable hepatocellular carcinoma.

Pomalidomide in combination with low-dose dexamethasone induced an overall response rate of up to 39% in patients with relapsed/refractory multiple myeloma with renal impairment.

Standard cisplatin-based concomitant chemoradiation induced superior disease-free survival compared with neoadjuvant chemotherapy followed by radical surgery in women with locally advanced squamous cervical cancer.

Investigators with the FDA’s Center for Drug Evaluation and Research and Oncology Center of Excellence conducted a pooled analysis of all trial reports and data marketing applications for the use of anti–PD-1 antibodies alone or in combination to treat patients with unresectable or metastatic melanoma.

The addition of pembrolizumab to stereotactic body radiotherapy induced an objective response rate of 13.2% among patients with advanced solid tumors.

The FDA's Oncologic Drugs Advisory Committee is slated to review a supplemental biologics license application for the use of blinatumomab for the treatment of patients with minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia.

Avelumab (Bavencio) missed the primary endpoint of improving overall survival in pretreated patients with non–small cell lung cancer, according to findings from the phase III JAVELIN Lung 200 Trial.

Treatment with the investigational agent DNX-2401 resulted in 20% of a cohort of patients with recurrent malignant glioma surviving more than 3 years from the time of treatment.

Denosumab was noninferior to zoledronic acid in preventing skeletal-related event in patients with newly diagnosed multiple myeloma.

The FDA has granted a priority review to a new drug application for lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer who have progressed on 1 or more ALK TKIs.

Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer.

PARP inhibitor combination regimens have the potential to enhance the relatively modest benefit offered by several monotherapy approaches used for the treatment of patients with ovarian cancer.

Many endometrioid cancers express high RNA levels for multiple immune checkpoints, and this may allow physicians to treat these patients with combination immune therapies.

Adjuvant therapy, regardless of the treatment modality, did not improve overall survival compared with observation for women with early stage, uterine-confined leiomyosarcoma.

The administration of stereotactic body radiation therapy through the use of CyberKnife therapy appears to be a safe and effective salvage treatment for women with previously irradiated, locally recurrent gynecologic cancer.

An analysis of black women of Caribbean descent with type I or type II endometrial cancer showed that this population expressed significant differences in genetic variations compared with a nationwide population of patients with endometrial cancer.